Karmele Valencia

Dr. Karmele Valencia

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAdrian Vallejo
Adrian Vallejo
Naiara PerurenaNaiara Perurena
Naiara Perurena
EGElisabet Guruceaga
Elisabet Guruceaga
PMPawel K. Mazur
Pawel K. Mazur
SMSusana Martinez-Canarias
Susana Martinez-Canarias
SVSilvestre Vicent
Silvestre Vicent
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative therapeutic strategies. Here we report the identification of a common transcriptional signature across mutant KRAS cancers of distinct tissue origin that includes the transcription factor FOSL1. High FOSL1 expression identifies mutant KRAS lung and pancreatic cancer patients with the worst survival outcome. Furthermore, FOSL1 genetic inhibition is detrimental to both KRAS-driven tumour types. Mechanistically, FOSL1 links the KRAS oncogene to components of the mitotic machinery, a pathway previously postulated to function orthogonally to oncogenic KRAS. FOSL1 targets include AURKA, whose inhibition impairs viability of mutant KRAS cells. Lastly, combination of AURKA and MEK inhibitors induces a deleterious effect on mutant KRAS cells. Our findings unveil KRAS downstream effectors that provide opportunities to treat KRAS-driven cancers.

6 February 2014 in Molecular Oncology
Verified
Journal Article
Open access
KVKarmele Valencia
Karmele Valencia
DLDiego Luis-Ravelo
Diego Luis-Ravelo
NBNicolas Bovy
Nicolas Bovy
IAIker Antón
Iker Antón
SMSusana Martínez-Canarias
Susana Martínez-Canarias
FLFernando Lecanda
Fernando Lecanda
Bone metastasis represents one of the most deleterious clinical consequences arising in the context of many solid tumors. Severe osteolysis results from tumor cell colonization of the bone compartment, a process which entails reciprocal exchange of soluble signals between tumor cells and their osseous microenvironment. Recent evidence indicates that tumor‐intrinsic miRNAs are pleiotropic regulators of gene expression. But they are also frequently released in exosome‐like vesicles (ELV). Yet the functional relevance of the transference of tumor‐derived ELV and their miRNA cargo to the extracellular milieu during osseous colonization is unknown.Comparative transcriptomic profiling using an in vivo murine model of bone metastasis identified a repressed miRNA signature associated with high prometastatic activity. Forced expression of single miRNAs identified miR‐192 that markedly appeased osseous metastasis in vivo, as shown by X‐ray, bioluminescence imaging and microCT scans. Histological examination of metastatic lesions revealed impaired tumor‐induced angiogenesis in vivo, an effect that was associated in vitro with decreased hallmarks of angiogenesis. Isolation and characterization of ELV by flow cytometry, Western blot analysis, transmission electron microscopy and nanoparticle tracking analysis revealed the ELV cargo enrichment in miR‐192. Consistent with these findings, fluorescent labeled miR‐192‐enriched‐ELV showed the in vitro transfer and release of miR‐192 in target endothelial cells and abrogation of the angiogenic program by repression of proangiogenic IL‐8, ICAM and CXCL1. Moreover, in vivo infusion of fluorescent labeled ELV efficiently targeted cells of the osseous compartment. Furthermore, treatment with miR‐192 enriched ELV in a model of in vivo bone metastasis pre‐conditioned osseous milieu and impaired tumor‐induced angiogenesis, thereby reducing the metastatic burden and tumor colonization.Changes in the miRNA‐cargo content within ELV represent a novel mechanism heavily influencing bone metastatic colonization, which is most likely relevant in other target organs. Mechanistic mimicry of this phenomenon by synthetic nanoparticles could eventually emerge as a novel therapeutic approach.

14 February 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KVKarmele Valencia
Karmele Valencia
COCristina Ormazábal
Cristina Ormazábal
CZCarolina Zandueta
Carolina Zandueta
DLDiego Luis-Ravelo
Diego Luis-Ravelo
IAIker Antón
Iker Antón
FLFernando Lecanda
Fernando Lecanda
Purpose: We investigated the role of the collagen-binding receptor discoidin domain receptor-1 (DDR1) in the initiation and development of bone metastasis.

1 March 2022 in Cancer Letters
Verified
Journal Article
Closed access
SOSergio Ortiz-Espinosa
Sergio Ortiz-Espinosa
XMXabier Morales
Xabier Morales
YSYaiza Senent
Yaiza Senent
DADiego Alignani
Diego Alignani
BTBeatriz Tavira
Beatriz Tavira
RPRuben Pio
Ruben Pio

13 June 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FEFrancisco Exposito
Francisco Exposito
MRMiriam Redrado
Miriam Redrado
MHMaeva Houry
Maeva Houry
KHKatherine Hastings
Katherine Hastings
MMMagdalena Molero-Abraham
Magdalena Molero-Abraham
ACAlfonso Calvo
Alfonso Calvo
Immunotherapy resistance in non–small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can be shaped by the mutational landscape of the tumor. Here, we observed genetic alterations in the PTEN/PI3K/AKT/mTOR pathway and/or loss of PTEN expression in >25% of patients with NSCLC, with higher frequency in lung squamous carcinomas (LUSC). Patients with PTEN-low tumors had higher levels of PD-L1 and PD-L2 and showed worse progression-free survival when treated with immunotherapy. Development of a Pten-null LUSC mouse model revealed that tumors with PTEN loss were refractory to antiprogrammed cell death protein 1 (anti–PD-1), highly metastatic and fibrotic, and secreted TGFβ/CXCL10 to promote conversion of CD4+ lymphocytes into regulatory T cells (Treg). Human and mouse PTEN-low tumors were enriched in Tregs and expressed higher levels of immunosuppressive genes. Importantly, treatment of mice bearing Pten-null tumors with TLR agonists and anti-TGFβ antibody aimed to alter this immunosuppressive microenvironment and led to tumor rejection and immunologic memory in 100% of mice. These results demonstrate that lack of PTEN causes immunotherapy resistance in LUSCs by establishing an immunosuppressive tumor microenvironment that can be reversed therapeutically. Significance: PTEN loss leads to the development of an immunosuppressive microenvironment in lung cancer that confers resistance to anti–PD-1 therapy, which can be overcome by targeting PTEN loss–mediated immunosuppression.

16 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CBCora Palanca Ballester
Cora Palanca Ballester
ARAitor Rodriguez-Casanova
Aitor Rodriguez-Casanova
STSusana Torres-Martínez
Susana Torres-Martínez
SCSilvia Calabuig-Fariñas
Silvia Calabuig-Fariñas
FEFrancisco Exposito
Francisco Exposito
ACAlfonso Calvo
Alfonso Calvo
Early alterations in cancer include the deregulation of epigenetic events such as changes in DNA methylation and abnormal levels of non-coding (nc)RNAs. Although these changes can be identified in tumors, alternative sources of samples may offer advantages over tissue biopsies. Because tumors shed DNA, RNA, and proteins, biological fluids containing these molecules can accurately reflect alterations found in cancer cells, not only coming from the primary tumor, but also from metastasis and from the tumor microenvironment (TME). Depending on the type of cancer, biological fluids encompass blood, urine, cerebrospinal fluid, and saliva, among others. Such samples are named with the general term “liquid biopsy” (LB). With the advent of ultrasensitive technologies during the last decade, the identification of actionable genetic alterations (i.e., mutations) in LB is a common practice to decide whether or not targeted therapy should be applied. Likewise, the analysis of global or specific epigenetic alterations may also be important as biomarkers for diagnosis, prognosis, and even for cancer drug response. Several commercial kits that assess the DNA promoter methylation of single genes or gene sets are available, with some of them being tested as biomarkers for diagnosis in clinical trials. From the tumors with highest incidence, we can stress the relevance of DNA methylation changes in the following genes found in LB: SHOX2 (for lung cancer); RASSF1A, RARB2, and GSTP1 (for lung, breast, genitourinary and colon cancers); and SEPT9 (for colon cancer). Moreover, multi-cancer high-throughput methylation-based tests are now commercially available. Increased levels of the microRNA miR21 and several miRNA- and long ncRNA-signatures can also be indicative biomarkers in LB. Therefore, epigenetic biomarkers are attractive and may have a clinical value in cancer. Nonetheless, validation, standardization, and demonstration of an added value over the common clinical practice are issues needed to be addressed in the transfer of this knowledge from “bench to bedside”.